X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Chicago misses out in AbbVie-Calico pharma deal

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Americas, News

A few days ago, Calico, a Google-backed biotech company, announced that it would build a California-based research and development facility to invent new drugs to combat diseases afflicting the elderly.

Half of the initial $500 million investment would be footed by AbbVie, a pharma company based in the Chicago area, for a few more months at least.

AbbVie’s CEO, Richard Gonzalez, and its board, which includes former United Airlines CEO Glenn Tilton, Northern Trust CEO Frederick Waddell and former Allstate CEO Edward Liddy, has made the unpopular decision to use its acquisition of European competitor Shire to move its headquarters to Ireland to lower its tax bill.

And now it also has decided to invest in a second California facility — presumably one not far from its existing research facility in Redwood City — rather than here, where its former parent company has roots dating to 1888.

That represents another missed opportunity for Chicago and Illinois, whose political leaders constantly tout the need for new research and development projects.

AbbVie defenders say this isn’t a loss. Profits will be split down the middle. AbbVie will take responsibility for testing and making the drugs that come out of Calico’s test tubes.

There’ll be plenty of “downstream opportunity” in Chicago, meaning after the scientific breakthrough occurs, said Michael Kope, CEO of the SENS Research Foundation, a Silicon Valley-based charity that works on cures for age-related diseases.

Downstream. That’s where Chicago aspires to be, right?

Consider the few research and development wins Chicago can tout in the last few years.

There was the $70 million grant over five years from the U.S. Department of Defense for a digital manufacturing lab. State and local governments kicked in $26 million more. And private companies made commitments that boosters claim brought the total to $320 million. (City officials have refused to disclose how much of that was in-kind vs. cash.)

There’s also a $120 million grant over five years from the U.S. Department of Energy for battery research at Argonne National Laboratory.

Compare that to Calico and AbbVie’s privately funded effort, which, if all goes well, will amount to a $1.5 billion investment.

The mayor’s office didn’t even know such a project was in play, even though one of AbbVie’s board members serves on the board of World Business Chicago, which is supposed to be this city’s corporate cheerleader-in-chief.

“AbbVie and Google have not discussed their plans with us,” said David Roeder, a spokesman for the state’s economic development agency. “As publicly traded companies, they have to be careful about disclosure of pending deals. News accounts indicate they plan to build in California. We are eager to discuss with them opportunities in Illinois.”

Biotech is a Bay Area strength, but the region hasn’t dominated the health care industry in the way it has the software and computing world. That is changing.

“The reality is that we’re seeing the consumerization of health care,” said Glen Tullman, the former Allscripts chief executive, whose Chicago-based 7wire Ventures invests in health care technology companies. “If you look at every other industry, the consumerization of those industries has by and large been led out of Silicon Valley. There’s a lot of talent out there that understands how to take everything from a basic service or an iPhone and apply them to health care.”

Data prepared by accounting firm EY for an industry trade group show that as of 2011, the biotech industry employed 230,177 people in California and 81,115 in Illinois. Research and development expenditures in 2010 in California amounted to $4.7 billion and in Illinois to $608 million.

Tags: AmericaChicago misses out in AbbVie-Calico pharma deal
Previous Post

Beacon Hill Launches New Division - Beacon Hill Pharma

Next Post

Halaven - Treatment of Metastatic Breast Cancer, Japan

Related Posts

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Next Post

Halaven - Treatment of Metastatic Breast Cancer, Japan

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In